Table 1.
Case | Age (years) | Sex | Origin | Histology | Stage | Other sites of involvement | Karyotype | RT-PCR product |
---|---|---|---|---|---|---|---|---|
1* | 45 | F | Lung | LG | IVA | Hilar LN, Pleural effusion | 46,XX,t(11;18)(q21;q21) | + |
2* | 51 | M | Lung | LG | IA | — | 46,XY,t(11;18)(q21;q21) | + |
3* | 63 | F | Lung | LG | IA | — | 46,XX,t(11;18)(q21;q21), inv(16)(p13q22) | + |
4* | 45 | M | Colon | LG+H | IIA | Mesenteric LN | 46,XY,t(11;18)(q21;q21) | + |
5* | 56 | M | Colon | LG | IA | — | 46,XY,t(11;18)(q21;q21) | + |
6 | 61 | M | Lung | LG | IIA | Orbit | N.A. | − |
7 | 76 | M | Lung | LG | IA | — | N.A. | + |
8 | 63 | F | Lung | LG | IA | — | N.A. | + |
9 | 56 | M | Lung | LG | IIA | Salivary gland | N.A. | − |
10 | 74 | F | Lung | LG | IA | — | N.A. | − |
11 | 57 | F | Lung | LG | IA | — | N.A. | − |
12 | 72 | F | Stomach | LG+H | IIA | Gastric LN | N.A. | − |
13 | 39 | M | Stomach | LG | IA | — | N.A. | + |
14 | 38 | M | Stomach | LG | IA | — | N.A. | − |
15 | 67 | M | Stomach | LG+H | IIIA | Paratracheal LN Retroperitoneal LN | N.A. | − |
16 | 54 | F | Stomach | LG | IA | — | N.A. | − |
17 | 46 | M | Stomach | LG | IA | — | N.A. | − |
18 | 60 | F | Stomach | LG | IA | — | N.A. | − |
19 | 45 | F | Stomach | LG | IA | — | N.A. | − |
20 | 27 | M | Stomach | LG+H | IA | — | N.A. | − |
21 | 54 | F | Stomach | LG+H | IIA | Gastric LN | N.A. | − |
22 | 63 | M | Stomach | HG+L | IVA | Testis, Orbit Retroperitoneal LN | N.A. | − |
*Cases 1 through 5 are identical to the cases previously studied. 18
LG, low grade; LG+H, low grade with partially high grade component; HG+L, high grade with residual low grade component; LN, lymph node; N.A., not available.